Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Xiaoshu Dai"'
Autor:
Xiaoshu Dai, Michael D. Karol, Matthew Hitron, Marjie L. Hard, John Evan Blanchard, Nicola C. J. E. Eraut, Natalie Rich, Brandon T. Gufford
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021)
Abstract This phase 1, open‐label study assessed14C‐napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites (primary objectives); safety/tolerability were also evaluated. Eight healthy males (1
Externí odkaz:
https://doaj.org/article/10ac3b8997ef4b199f99a49697b69367
Autor:
Matthew Hitron, Michael D. Karol, Marjie L. Hard, Xiaoshu Dai, Colleen F. Mclaughlin, Scott J. Brantley, Matthew T. Goulet
Publikováno v:
Clinical Pharmacology in Drug Development
Napabucasin is an orally administered reactive oxygen species generator that is bioactivated by the intracellular antioxidant nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1. Napabucasin induces cell death in cancer cells, includ
Autor:
Xiaoshu Dai Gurov, Elizabeth Merica, Varsha Iyer, Annie Claeys, Spurthi Patil, Rolandas Urbstonaitis, James Xiao, Michael U. Callaghan
Publikováno v:
Blood. 140:5426-5427
Autor:
Michael D. Karol, John Evan Blanchard, Marjie L. Hard, Xiaoshu Dai, Nicola C. J. E. Eraut, Matthew Hitron, Brandon T. Gufford, Natalie Rich
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives, Vol 9, Iss 1, Pp n/a-n/a (2021)
This phase 1, open‐label study assessed14C‐napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites (primary objectives); safety/tolerability were also evaluated. Eight healthy males (18–45 ye
Publikováno v:
Journal of Clinical Oncology. 39:477-477
477 Background: Napabucasin is an orally-administered NAD(P)H quinone dehydrogenase 1–bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including STAT3. Methods: Food effects on napabucasin pharmacokin
Autor:
Michael D. Karol, Marjie L. Hard, Scott J. Brantley, Xiaoshu Dai, Matthew T. Goulet, Colleen F. Mclaughlin, Matthew Hitron
Publikováno v:
Journal of Clinical Oncology. 38:142-142
142 Background: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including pSTAT3 through the generation of reactive oxygen species. This phase 1 open-label study evaluated the DD
Autor:
Nicola C. J. E. Eraut, Brandon T. Gufford, Marjie L. Hard, Xiaoshu Dai, Natalie Rich, Matthew Hitron, J Evan Blanchard, Michael D Karol
Publikováno v:
Molecular Cancer Therapeutics. 18:A113-A113
Introduction: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including pSTAT3 through the generation of reactive oxygen species. The primary objectives of this phase 1, open-lab
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Advanced Materials. 24:370-374
Staining and etching is developed for the fabrication of two-dimensional arrays and three-dimensional foam-like metallic nanostructures from a piece of tissue using a combination of metal staining and oxygen plasma etching. This novel nanofabrication
Autor:
Tanios Bekaii-Saab, Wahid Hanna, Laura Borodyansky, Sameh Mikhail, Alexander Starodub, Yue Chang, Cindy Oh, Wei Li, Xiaoshu Dai, Walid L. Shaib, Safi Shahda, Chiang Li, Anterpreet S. Neki, Anne M. Noonan, Bert H. O'Neil, Bassel F. El-Rayes, Emily Brooks
Publikováno v:
Journal of Clinical Oncology. 36:4110-4110
4110Background: NAPA is an oral investigational agent, hypothesized to inhibit cancer stemness pathways, including STAT3 pathway implicated in cancer stem-cell viability. We report updated data in ...